Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT07869004
Enrolling by invitation Observational

Intrauterine Fetal Growth Restriction and Fetuin-B

NCT07869004 · tracked via the Priya Life Science Turkey tracker
Sponsor
Karadeniz Technical University
Phase
Observational
Started
2026-10-30
Last updated
2026-10-09

Condition(s) studied

IUGR

Investigational drug(s) / intervention(s)

measure fetuin b

measure fetuin b: No intervention is administered. This is an observational study in which maternal serum fetuin-B levels are measured and compared between pregnant women with intrauterine growth restriction (IUGR) and pregnant women with appropriate-for-gestational-age (AGA) fetuses.

Study summary

\*\*Brief Summary\*\*

This study aims to evaluate the relationship between fetuin-B levels and intrauterine growth restriction (IUGR). Maternal serum fetuin-B levels will be compared between pregnant women with IUGR and those with appropriate fetal growth. The study will also assess whether fetuin-B levels are associated with clinical and obstetric characteristics, fetal growth parameters, and Doppler findings. The findings may provide further insight into the potential role of fetuin-B in the pathophysiology and clinical assessment of IUGR.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Pregnant women with a singleton pregnancy. * Gestational age between \[X and Y\] weeks at the time of enrollment. * Pregnant women diagnosed with intrauterine growth restriction (IUGR) according to predefined fetal growth and Doppler criteria for the study group. * Pregnant women with an appropriate-for-gestational-age (AGA) fetus for the control group. * Availability of maternal serum samples for fetuin-B measurement. * Provision of written informed consent to participate in the study. Exclusion Criteria: * Multiple pregnancy. * Major fetal congenital or chromosomal anomalies. * Known maternal chronic diseases that may significantly affect fetal growth or fetuin-B levels, such as pre-existing diabetes mellitus, chronic hypertension, renal disease, or autoimmune disease. * Maternal infection or other conditions associated with fetal growth restriction, when clinically relevant. * Placental abnormalities that may independently affect fetal growth. * Pregnancies with incomplete clinical, laboratory, ultrasonographic, or Doppler data. * Inability or unwillingness to provide informed consent.

Primary outcome measure(s)

  • Maternal Serum Fetuin-B Level — At the time of diagnosis of IUGR or at the corresponding gestational age in the control group. It is time between the 24th and 37th weeks of pregnancy.
    Maternal serum fetuin-B levels will be measured and compared between pregnant women with intrauterine growth restriction (IUGR) and pregnant women with appropriate-for-gestational-age (AGA) fetuses to evaluate the association between fetuin-B levels and IUGR.

Trial sites (1)

FacilityCityRegionStatus
Karadeniz technical university, school of medicine Akçaabat Trabzon

More Karadeniz Technical University trials in Turkey

Effect of Progressive Neck Motor Control Exercises on Temporomandibular Joint Dysfunction Recruiting
Percussive Massage Therapy and Muscle Architecture Recruiting
Examining the Effect of Mandala Art Therapy on Symptoms and Quality of Life in Multiple Sclerosis Patients Enrolling by invitation
Temporomandibular Joint Function, Oral Habits and Pain Complaints of Pregnant Women Recruiting
Effect of Informing Family Members of Patients During Surgery Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07869004 on ClinicalTrials.gov ↗ ← All trials in Turkey